View Drug - House Dust Mite, Dermatophagoides farinae
Jump to: Basic Info Purpose Indications Warnings Reactions

House Dust Mite, Dermatophagoides farinae

Generic: HOUSE DUST MITE, DERMATOPHAGOIDES FARINAE

100%
Basic Information
Manufacturer
Allermed Laboratories, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
CUTANEOUS
FDA Set ID
3b19e1e4-1a28-4515-ac20-cc4a9b2d45e6
Indications & Usage
INDICATIONS AND USAGE Standardized mite extract is indicated for use in the diagnosis of patients with a history of allergy to mites or house dust and for the treatment of patients with a history of mite allergy who have established sensitivity to mites by diagnostic skin testing.

The use of mite extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook (10).
Warnings
WARNINGS Concentrated extract must be diluted with sterile diluent prior to first use on a patient for treatment or intradermal testing.

All concentrates of allergenic extract are manufactured to assure high potency and therefore have the ability to cause serious local and systemic reactions, including death in sensitive patients (11).

Patients should be informed of this risk and precautions should be discussed prior to initiating immunotherapy (see PRECAUTIONS below).

Allergenic extract should be temporarily withheld from patients or the dose adjusted downward if any of the following conditions exist: 1) severe symptoms of rhinitis and/or asthma; 2) infection or flu accompanied by fever; 3) exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection.

The dosage must be reduced when starting a patient on fresh standardized mite extract or when transferring a patient from non-standardized or modified extract to standardized extract, even though the labeled strength of the old and new vials may be the same.

This is necessary due to a loss of extract potency during storage in the physician's office.

The mite allergen content of old and new extract may be compared and adjusted by dosage reduction and/or dilution before the new extract is administered.

The amount of new extract given should not exceed 25% of the last dose given from the old vial, assuming both extracts contain comparable amounts of mite allergen.

Any evidence of a local or generalized reaction requires a reduction in dosage during the initial stages of immunotherapy, as well as during maintenance therapy.

Beta-blocking drugs may make patients refractory to the usual dose of epinephrine, in the event epinephrine is required to treat an adverse allergic reaction.
Adverse Reactions
ADVERSE REACTIONS Adverse systemic reactions usually occur within minutes and consist primarily of allergic symptoms such as generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema and hypotension.

Less commonly, nausea, emesis, abdominal cramps, diarrhea and uterine contractions may occur.

Severe reactions may cause shock and loss of consciousness.

Fatalities have occurred rarely (11).

Systemic reactions occur with varying frequency in different clinics.

To some extent, the reaction rate is related to the type and dose of administered extract and to the degree of sensitivity of the patient.

Despite all precautions, occasional reactions are unavoidable.

Reports from regulatory authorities in Sweden to the Center for Biologics Evaluation and Research (CBER) indicated that several deaths have been associated with the use of mite extracts.

CBER was subsequently informed that these deaths may have been related to use by physicians or other health professionals untrained in the administration of potent allergens, rather than a product defect.

It should be noted that anaphylaxis and deaths following the injection of mite and other extracts also have been reported by the British Committee on Safety in Medicine in the British Medical Journal, 293:943, 1986.

Local reactions consisting of erythema, itching, swelling, tenderness and sometimes pain may occur at the injection site.

These reactions may appear within a few minutes to hours and persist for several days.

Local cold applications and oral antihistamines may be effective treatment.

For marked and prolonged local reactions, steroids may be helpful.

The treatment of systemic allergic reactions is somewhat dependent upon the symptom complex.

Epinephrine hydrochloride 1:1,000 aqueous, in an adult dose of 0.3 - 0.5 mL (or 0.01 mL per kg.

for children) administeredsubcutaneously in the opposite arm is the immediate treatment of choice.

A tourniquet should be placed above the site of the extract injection if the injection was done on the extremities.

Antihistamines may offer relief of recurrent urticaria, associated skin reactions and gastrointestinal symptoms.

Persistent wheezing may necessitate intravenous aminophylline treatment.

For profound shock and hypotension, intravenous fluids, vasopressors and oxygen also may be needed.

Maintenance of an open airway is critical if upper airway obstruction is present.

Corticosteroids may provide benefit if symptoms are prolonged or recurrent.